Drug Trial Radar · NCT06584032
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
412
Planned (sponsor's estimate)
Start
Dec 12, 2024
Primary completion
Jan 8, 2029
Study completion Jun 9, 2029
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Sep 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).
Conditions
- Advanced Endometrial Cancer
Interventions
fruquintinibDrug
Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.
sintilimabBiological
Sintilimab will be intravenously administrated on Day 1 every three weeks.
paclitaxelDrug
175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.
doxorubicinDrug
60mg/m\^2 via IV infusion, on Day 1 every three weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) as assessed by IRCTime frame: Up to approximately 4 years
- Overall Survival (OS)Time frame: Up to approximately 4 years
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Beijing Obstetrics and Gynecology Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
SUN Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Not yet recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
Xijing Hospital of Air Force Military Medical University
Xi'an, Shaanxi, China · Not yet recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Not yet recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Sencond Hospital of Shanxi Medical University
Taiyuan, Shanxi, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Not yet recruiting
Women's Hospital school of Medical Zhejiang University
Hangzhou, Zhejiang, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.